DelveInsight’s, “Schizophrenia Pipeline Insight” report provides comprehensive insights about 55+ companies and 60+ pipeline drugs in Schizophrenia pipeline landscape. It covers the Schizophrenia ...

With an understanding of the healthcare ecosystem, Sayer's expertise in strategy, transformation and payer negotiations is ...

Lyndra Therapeutics®, a clinical-stage biopharmaceutical company pioneering long-acting oral therapies, today announced the ...

Reviewers have tested some of the products below and may have received some products from the manufacturers for free. All opinions are the reviewers’ own. These full-spectrum gummies are ...

Lyndra’s long-acting oral therapies, including lead investigational product oral weekly risperidone (LYN-005), are designed to deliver medication for a week or longer with a single oral dose.

Given the favorable results, Lyndra elected to stop the study early. The biotech’s long-acting risperidone candidate is slated to enter a phase 3 safety trial in the first half of 2025.

Lyndra’s long-acting oral therapies, including lead investigational product oral weekly risperidone (LYN-005), are designed to deliver medication for a week or longer with a single oral dose.

Your doctor will decide on the dose of RISPERDAL CONSTA that is right for you. Because risperidone is released gradually into your body, you will need an injection only every two weeks.